Central retinal vein occlusion: Difference between revisions

No edit summary
Line 1: Line 1:
==Background==
==Background==
*Risk Factors
**DM
**HTN
**Hypercoagulable states
**Vasculitis
**Glaucoma
[[File:crvo.png|thumbnail|CRVO Blood and Thunder]]
[[File:crvo.png|thumbnail|CRVO Blood and Thunder]]
Risk Factors
*DM
*HTN
*Hypercoagulable states
*Vasculitis
*Glaucoma


==Clinical Features==
==Clinical Features==
Line 28: Line 29:


==Disposition==
==Disposition==


==See Also==
==See Also==

Revision as of 06:05, 24 February 2016

Background

  • Risk Factors
    • DM
    • HTN
    • Hypercoagulable states
    • Vasculitis
    • Glaucoma
CRVO Blood and Thunder

Clinical Features

  • Loss of vision
    • Variable, ranging from vague blurring to rapid, painless monocular vision loss

Differential Diagnosis

Acute Vision Loss (Noninflamed)

Emergent Diagnosis

Diagnosis

  • Fundoscopy
    • Optic disc edema, dilated and tortuous veins, diffuse retinal hemorrhages ("blood-and-thunder fundus")

Management

  • Consult ophtho and neuro
  • No treatment regimen provides significant and consistent results
  • Complex treatment possibly involving aspirin, anticoagulation, fibrinolysis, lowering IOP, topical steroids, cyclocryotherapy, photocoagulation, intravitreal injections (triamcinolone, anti-VEGF, aflibercept) while managing underlying medical diseases
  • Possible benefit from LMWH plus aspirin in central retinal vein occlusion[1]
    • May provide a 78% risk reduction of adverse ocular outcome in central vein occlusion
    • Less benefit in branched retinal vein occlusion

Disposition

See Also

Acute Vision Loss (Noninflamed)

References

  1. Lazo-Langner A et al. Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. Haematologica. 2010 Sep; 95(9): 1587–1593.